Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Muscle Invasive Bladder Urothelial Carcinoma 1

Interventions

Cisplatin 14Carboplatin 12Magnetic Resonance Spectroscopy 11Specimen Handling 10Gemcitabine 10pembrolizumab 8Pemetrexed 8atezolizumab 7Paclitaxel 7Radiotherapy, Intensity-Modulated 5Platinum 5Nivolumab 5Immunoglobulin G 5Doxorubicin 5Docetaxel 5Disulfides 5Bevacizumab 5130-nm albumin-bound paclitaxel 51,2-diaminocyclohexaneplatinum II citrate 5Cetuximab 4Biopsy 4durvalumab 3Temozolomide 3Standard of Care 3Rituximab 3Drug Therapy 3Dexamethasone 3Cyclophosphamide 3(225)Ac-DOTA-c(RGDyK) 3venetoclax 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2/3 × Circulating Tumor DNA × 30 days × Clear all
NCT05987241 2026-06-03

Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study

National Cancer Institute (NCI)

Phase 2/3 Recruiting
992 enrolled
Genitourinary

Muscle Invasive Bladder Urothelial Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡